BioTech Health X

Our BioTech Health X CEO Series continues with an exclusive interview with Dr. Emil Tsai of 心悅生醫 SyneuRx as he discusses the background and foundation of the company, how COVID-19 affected the business along with what is ahead in the years to come.

SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections Table of Contents Hide About SyneuRxAbout CEO Guochuan Emil Tsai, MD, Ph.D, MASCan you please introduce yourself and…

Leader in redosable gene therapy Krystal Biotech (Nasdaq: KRYS) announced today the U.S. Food and Drug Administration accepted the company’s Investigational New Drug (IND) application for the evaluation of KB407 in a cystic fibrosis (CF) clinical trial.

Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial Table of Contents Hide About Krystal Biotech’s KB407KB407 Phase 1 Trial OverviewCystic Fibrosis OverviewAbout Krystal Biotech, Inc. Leader…

Clinical-stage pharmaceutical company Brickell Biotech (Nasdaq: BBI) announced that the company has received formal notice from Nasdaq stating that Brickell has regained compliance meeting the minimum bid price requirement for continued listing on the exchange and, accordingly, the scheduled hearing has been canceled and Brickell’s common stock will continue to be listed and traded on Nasdaq.

Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement Brickell Biotech (Nasdaq: BBI) has regained compliance meeting the minimum bid price requirement for continued listing on Nasdaq exchange.

Today Merck announced that KEYTRUDA (pembrolizumab) Injection 100 mg has failed the Phase 3 clinical trial KEYNOTE-412 evaluating the company’s anti-PD-1 therapy with concurrent chemoradiation therapy that was followed by Keytruda as maintenance therapy in a Keytruda regimen.

The trial did not meet its primary endpoint which was event-free survival (EFS) for treatment of patients with unresected locally advanced head and neck squamous cell carcinoma (HNSCC).

Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…